European oncology market access is changing. Since January 2025, new cancer medicines must undergo EU joint clinical assessments alongside EMA review, while national HTA bodies continue to refine evidence requirements across member states. For many submissions, teams rely on real-world data to address comparative effectiveness, heterogeneous PICO needs, and compressed dossier timelines. As demand for faster, higher-quality evidence grows, organizations are also exploring how AI and advanced analytics can support evidence generation and analysis.
In this webinar, the expert panel disucssed:
- How EU joint clinical assessment and national HTA processes are changing evidence expectations for oncology medicines across member states.
- Where real-world data adds the most value in HTA submissions, from comparator selection to supplementing immature or single-arm trial evidence.
- How multinational oncology real-world data can support both global and country-specific evidence needs in market access planning.
- Practical strategies for proactive evidence planning within compressed joint clinical assessment timelines and across heterogeneous PICO requirements.
- How advanced analytics and AI are being applied to accelerate real-world evidence generation and analysis—and what that means for HTA-ready evidence across Europe.
